Table 3.
Multivariate analysis of prognostic factors on clinical results for very elderly EC
| Endpoint | Prognostic factors | Multivariate analysis | |
|---|---|---|---|
| P | HR (95% CI) | ||
| 2‐year OS | NRI before RT (<100 vs. ≥100) | 0.039 | 0.887 (0.360–0.972) |
| NLR before RT (<2.5 vs. ≥2.5) | <0.001 | 2.452 (1.513–3.972) | |
| AJCC stage (I–II vs. III) | 0.019 | 1.858 (1.108–3.114) | |
| 2‐year LRFFS | NLR before RT (<2.5 vs. ≥2.5) | 0.006 | 2.053 (1.227–3.436) |
| AJCC stage (I–II vs. III) | 0.001 | 2.620 (1.453–4.723) | |
| PGTV dose (<60 Gy vs. ≥60 Gy) | 0.045 | 0.891 (0.463–0.984) | |
| 2‐year DMFS | NRI before RT (<100 vs. ≥100) | 0.046 | 0.441 (0.128–0.992) |
| Chemotherapy (No vs. Yes) | 0.043 | 3.206 (1.080–6.451) | |
AJCC, American Joint Committee on Cancer; DMFS, distance metastasis‐free survival; LRFFS, local–regional failure‐free survival; NLR, neutrophil–lymphocyte ratio; NRI, nutritional risk index; OS, overall survival; PGTV, planning gross tumor volume; RT, radiotherapy.